Evaxion Biotech A/S (Nasdaq: EVAX)

https://www.evaxion-biotech.com

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections. *

	Start	2008-01-01 established
	Industry	vaccine
	Industry 2	AI-immunology™ platform
	Person	Wegner, Lars Staal (Evaxion Biotech 201707– CEO before 10y at Bavarian Nordic before Pfizer)
	Person 2	Vraniak, Glenn S. (Evaxion Biotech 201910– CFO before electroCore + G&W Laboratories + Aprecia Pharmaceuticals)

	Region	København (Copenhagen)
	Country	Denmark
	Street	34E Bredgade
	City	1260 København K
		Address record changed: 2021-02-20

Basic data	Employees	B: 11 to 50 (2020-12-31)
	Currency	USD
	Profit	-15,018,000 (2020-12-31)
	Cash	5,834,000 (2020-12-31)

		* Document for »About Section«: Evaxion Biotech A/S. (2/10/21). "Press Release: Evaxion Biotech Closes Its U.S. Initial Public Offering of American Depositary Shares". Copenhagen.

		Record changed: 2024-02-12